The Effect of Receptor Status on Lymph Node Involvement and its Impact on the Survival of Breast Cancer Patients

Sheikhaliyan, A; Tajvidi, M; Atashgar, K; Abdi, P

The Effect of Receptor Status on Lymph Node Involvement and its Impact on the Survival of Breast Cancer Patients

Document Type : Original Article

Authors

A Sheikhaliyan ¹

M Tajvidi ²

K Atashgar ³

P Abdi ⁴

¹ Master of Science in Industrial Engineering, Malek Ashtar University of Technology

² ** Assistant Professor, Department of Radiotherapy and Oncology, Isfahan University of Medical Sciences

³ Associated Professor of Malek Ashtar University of Technology, Department of Industrial Engineering, Tehran, Iran

⁴ Associate Professor and Faculty Member, Industrial Engineering Complex, Malek Ashtar University of Technology

Abstract

Introduction & Objective: Breast cancer is known as the most common site-specific cancer as well as it is referred to as the second cause of mortality for women. Literature indicates that the most important prognostic factors are addressed by lymph node involvement, the activity of estrogen and progesterone receptors, tumor size, tumor grade, histologic type, and epidermal growth factor. Published researches address that these prognostic factors and the relationship between them are known as important indicators to assess the effectiveness of diagnosis of a treatment method and a treatment method influence of the breast cancer. However the published researches do not address analyzing the impact of the receptor status on lymph node involvement and the impact of the relationship between the prognostic factors on survival of patients with breast cancer. This study attempts to not only investigating the impact of the receptors on lymph node involvement, but also the survival of breast cancer patients considering simultaneously the receptor status and lymph node involvement prognostics, is analyzed. Materials & Methods: In this study, 1822 patients diagnosed with breast cancer have been considered. These patients after treating in the period of 2007 till mid 2016 were cared under adjuvant therapy such as hormone therapy, chemotherapy and radiotherapy. In this study, receptor groups are defined in 8 categories based on different combinations, as well as the number of lymph nodes involvement are categorized in 4 branches (i.e. no lymph node involvement, between 1-3 lymph nodes involvement, between 4-9 lymph nodes involvement, and more than 9 lymph nodes involvement). Receptor statuses of these patients were analyzed using the logistic regression approach. In this research, the statistical software R has been used for data analysis. Results: The age mean (± Standard deviation) of the patients were addressed by 50.45 (±11.47) years. Lymph node involvement was recognized for more than half of the patients (933 people i.e. 51.20%). The frequency of each 8 receptor groups were obtained as (263 individuals) 14.43%, (222 individuals) 12.18%, (762 individuals) 41.82%, (138 individuals) 7.57%, (40 individuals) 2.19%, (70 individuals) 3.84%, (11 individuals) 0.54%, (22 individuals) 1.20%, respectively. Group 3 of the receptor status (i.e. simultaneous prognostics of positive estrogen, positive progesterone, and negative HER2), addressed the highest percentage of (762 individuals) 41.82%, and Group 7 (i.e. simultaneous prognostics of negative estrogen, positive progesterone, and HER2-positive) addressed the lowest percentage of (11 individuals) 0.54% among the other groups. P-value is addressed by 0.01 and 0.05 for estrogen and HER2, respectively, when the impact of receptors on lymph nodes has been analyzed. Conclusions: This study indicated that: 1) there exist relationship between estrogen receptors and Her2 with lymph node involvement, so that these receptors impact on involving the lymph nodes. 2) In the case that the prognostics of positive estrogen, positive progesterone, and negative Her2 occur simultaneously, the receptor status addresses the best condition of the survival for a patient with breast cancer compared to other groups.

Keywords

Receptor Status

Lymph Node Involvement

Survival Analysis

1. Gohari MR, Mokhtari Hesari P, Moghaddami Fard Z, Khodabakhshi R. Determining pattern of metastasis and prognostic factors in breast cancer using conditional regression model (PWP). Scientific Journal of School of Public Health and Institute of Public Health Research. 2014; 12(1): 41-51.

2. Colon E, Rayer JS, Gonzalez Keelan C, Climent peris C. Prevalence of steroied Receptor and Her-2/Neu in Breast biopsies of women living in puertorico. Journal of Puertorice health-sciences. 2002; 21(4): 299-303.

3. Sharif Sistani N, Sadeghian M. H, Homaei F, Haghighati F. Immunohistochemical Study of cell proliferation marker,estrogen and progesterone receptors in breast carcinoma. Birjand Univ med Sci 2006; 13(3): 38-45.

4. Naghshvar F, Torabizadeh Zh, EmadianO, Zare A,Ghahremani M. Status of estrogene, progesterone receptors and HER-2/neu expression in invasive breast cancer. Gorgan University Medical Science. 2007; 8(4): 64-67.

5. Li MH, Hou CL, Wang C, Sun AJ. HER-2, ER, PR status concordance in primary breast cancer and corresponding metastatic lesion in lymph node in Chinese women. Pathol Res Pract. 2016; 212(4):
252-257.

6. Sheikhpour, R., & Mohiti Ardekani, J. The effect of progesterone on p53 protein in T47D cell line. Urmia Medical Journal. 2014; 25(10): 954-960.

7. Hashemi M, Ghavami S. Effects of estradiol, progesterone and testosterone on proliferation of human breast cancer cell lines. Zahedan university of Medicalscience and Health Services. 2005; 7(1):
21-29.

8. Mirzaei HR, Sabahat A, Nasrollahi F,
Mohammadi-Yeganeh L. Correlation between ER, PR, HER2 receptors and prognostic factors in breast cancer. Pejouhandeh 2010; 15(4): 152-156.

9. Moradi Marjaneh M, Homaei Shandiz F, Shamsian A, Eftekharzadeh Mashhadi I, Hedayati Moghaddam M.R, Bidkhori H.R, Ghafarzadegan K. Prognostic role of her2/new, P53, ER and PR in Breast Cancer: First report from northeast of iran. 2008; 2(1): 7-17.

10. Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, Imamura M, Takatsuka Y, Sakita I, Hatada T, Miyoshi Y. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen
Receptor-Positive and HER2-Negative Breast Cancer. Clinical Breast Cancer 2014.

11. Shakeri M, Ghavami Ghanbarabadi V, Esmaeili H, Gabbari Noghabi H, Homaei Shandiz F, Baghishani H. Analysis of survival data of patients with breast cancer with Cox proportional hazards model for dependent censoring based on copula function. Journal of North Khorasan University of Medical Sciences.2011; 3: 53-64.

12. Saunders Ch, Jassal, S. Breast cancer. Oxford University Press. 2009; (1. ed.). Chapter 13.

13. Alizadeh SA, Moshfeghi K, Kalantari M,Ebrahimi Kh. Lymph -node involvement and tumor markers in patients with breast cancer. Arak Medical University Journal. 2010; 12(4): 44-50.

14. Endo A, Shibata T, Tanaka H. Comparison of seven algorithms to predict breast cancer survival. Survival. 2008; 30: 11-16.

15. Abdolmaleki P, Yarmohammadi M, Gity M. Comparison of logistic regression and neural network models in predictin the outcome of biopsy in breast cancer from MRI findings. Iranian Journal of Radiation Research.2004; 1: 217-228.

16. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjänen K. Hormone receptors as prognostic factors in female breast cancer. Annals of Medicine 1991; 23(6): 643-648.

17. Biesterfeld S, Klüppel D, Koch R, Schneider S, Steinhagen G, Mihalcea AM, Schröder W. Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistochemistry of the most positive tumor focus. Journal of Pathology. 1998; 185: 25.